GoldenGolden
Advanced Search
SiteOne Therapeutics

SiteOne Therapeutics

SiteOne Therapeutics is a Bozeman, Montana-based developer of products for therapeutics and diagnostics.

SiteOne Therapeutics is a clinical-stage biopharmaceutical company that develops and produces therapeutics for treating hypersensitivity disorders such as chronic cough, itch and pain. Its drug candidates are exquisitely selective inhibitors of voltage-gated sodium ion channels that are under investigation for the treatment of multiple neurogenic diseases by systemic and local routes of administration.

SiteOne Therapeutics develops novel pain therapeutics that are meant to provide treatment for acute and chronic pain. It's drugs deliver treatment to neuropathic pain via novel pain therapeutics without showing the limitations of existing drugs, such as opioids, and it enables healthcare professionals to provide an effective treatment to their patients and enhance efficiency in healthcare delivery.

SiteOne is creating a new class of non-opioid treatments that selectively interrupts electrical signals from hyperexcitable, peripheral sensory nerves before engaging the central nervous system.

Timeline

January 6, 2017
SiteOne Therapeutics raises a $15,000,000 series B round from Amgen.
January 2017
SiteOne Therapeutics raises a $15,000,000 series B round from 2M Companies, Amgen, BioBrit, Mission Bay Capital, Next Frontier Capital, Sears Capital Management and Z Investments.

Funding rounds

People

Name
Role
LinkedIn

Further reading

Title
Author
Link
Type
Date

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

News

Title
Author
Date
Publisher
Description
May 11, 2021
BioSpace
SiteOne Therapeutics Announces $1.73M Grant from NIH/NHLBI and Adds Respiratory Advisory Team - read this article along with other careers information, tips and advice on BioSpace
SiteOne Therapeutics
April 20, 2021
www.prnewswire.com:443
/PRNewswire/ -- SiteOne Therapeutics, Inc., a clinical-stage biopharmaceutical company developing new treatments to address conditions involving...
Fraiser Kansteiner
March 25, 2021
FierceBiotech
GlaxoSmithKline and Centessa Pharmaceuticals cut ties with Moncef Slaoui after an employee raised allegations of sexual harassment that occurred several years ago at GSK. AlloVir nabbed Gilead Sciences' virology lead Diana Brainard as its new CEO. Merck has tapped longtime insider Caroline Litchfield as chief financial officer.
BioSpace
May 18, 2020
BioSpace
Jubilant Biosys recently sat down with Hassan Pajouhesh, Ph.D., Director of Medicinal Chemistry at SiteOne Therapeutics, a private biopharmaceutical company dedicated to developing novel pain therapeutics, to discuss some of the latest developments in the industry and at SiteOne.

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.